Actinium Pharmaceuticals, Inc. (Delaware) (ATNM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATNM POWR Grades
- Value is the dimension where ATNM ranks best; there it ranks ahead of 57.45% of US stocks.
- The strongest trend for ATNM is in Stability, which has been heading down over the past 177 days.
- ATNM ranks lowest in Stability; there it ranks in the 4th percentile.
ATNM Stock Summary
- ACTINIUM PHARMACEUTICALS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 9.13% of US listed stocks.
- With a price/sales ratio of 288.71, ACTINIUM PHARMACEUTICALS INC has a higher such ratio than 98.67% of stocks in our set.
- With a year-over-year growth in debt of 517.81%, ACTINIUM PHARMACEUTICALS INC's debt growth rate surpasses 96.5% of about US stocks.
- Stocks that are quantitatively similar to ATNM, based on their financial statements, market capitalization, and price volatility, are VBLT, BLDP, GLYC, TMBR, and VSTM.
- ATNM's SEC filings can be seen here. And to visit ACTINIUM PHARMACEUTICALS INC's official web site, go to www.actiniumpharma.com.
ATNM Valuation Summary
- ATNM's price/earnings ratio is -9.3; this is 142.08% lower than that of the median Healthcare stock.
- ATNM's price/sales ratio has moved NA NA over the prior 123 months.
Below are key valuation metrics over time for ATNM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ATNM | 2023-01-30 | 269.6 | 4.0 | -9.3 | -5.7 |
| ATNM | 2023-01-27 | 279.8 | 4.1 | -9.7 | -6.1 |
| ATNM | 2023-01-26 | 276.8 | 4.1 | -9.6 | -6.0 |
| ATNM | 2023-01-25 | 270.3 | 4.0 | -9.4 | -5.8 |
| ATNM | 2023-01-24 | 275.1 | 4.1 | -9.5 | -5.9 |
| ATNM | 2023-01-23 | 280.7 | 4.1 | -9.7 | -6.1 |
ATNM Growth Metrics
- Its 2 year cash and equivalents growth rate is now at 1034.79%.
- The year over year net cashflow from operations growth rate now stands at 1.87%.
- Its 5 year net income to common stockholders growth rate is now at 21.73%.
The table below shows ATNM's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1.053 | 11.37 | -30.38 |
| 2022-06-30 | 1.241 | 11.497 | -27.329 |
| 2022-03-31 | 1.462 | -21.005 | -24.583 |
| 2021-12-31 | 1.144 | -20.866 | -24.774 |
| 2021-09-30 | 1.121 | -22.072 | -23.144 |
| 2021-06-30 | 0.888 | -21.478 | -22.261 |
ATNM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ATNM has a Quality Grade of F, ranking ahead of 4.49% of graded US stocks.
- ATNM's asset turnover comes in at 0.013 -- ranking 384th of 681 Pharmaceutical Products stocks.
- EIGR, MNOV, and ATRA are the stocks whose asset turnover ratios are most correlated with ATNM.
The table below shows ATNM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.013 | 1 | 14.970 |
| 2021-03-31 | 0.010 | 1 | 14.068 |
| 2020-12-31 | 0.000 | NA | 13.639 |
| 2020-09-30 | 0.000 | NA | 11.983 |
| 2020-06-30 | 0.000 | NA | 11.318 |
| 2020-03-31 | 0.000 | NA | 10.911 |
ATNM Stock Price Chart Interactive Chart >
ATNM Price/Volume Stats
| Current price | $12.21 | 52-week high | $15.12 |
| Prev. close | $11.93 | 52-week low | $4.41 |
| Day low | $11.75 | Volume | 219,900 |
| Day high | $12.25 | Avg. volume | 284,817 |
| 50-day MA | $10.73 | Dividend yield | N/A |
| 200-day MA | $7.84 | Market Cap | 311.15M |
Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) Company Bio
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The companys targeted radio immunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213, and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The company was founded in 2000 and is based in New York City, New York.
Latest ATNM News From Around the Web
Below are the latest news stories about ACTINIUM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ATNM as an investment opportunity.
Actinium Pharmaceuticals, Inc. to Present at the 3rd Annual B. Riley Securities Oncology ConferenceActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company's management team will participate in a fireside chat on Thursday, January 19, 2023 at 10:30 AM EST at the 3rd Annual B. Riley Securities Oncology Conference. The webcast of the presentation will be accessible on the event's website at https://brileyoncology22.sequireevents.com/ and on the investor relations page of Actinium's we |
Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem MeetingsActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that data from its pivotal Phase 3 SIERRA trial of Iomab-B have been accepted as a late-breaker presentation at the Transplantation & Cellular Therapy (TCT) Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). TCT, the largest bone ma |
Actinium Pharmaceuticals: Prep For February2023 will be a big year for Actinium Pharmaceuticals (ATNM). After stellar phase 3 and phase 1 results were reported last quarter, the clinical-stage biotech is starting out the new year with a lot of momentum. Expect market interest to build as we approach an important conference in mid-February. Actinium is dedicated to the commercialization of targeted radiotherapies which will fulfill the unmet needs in various cancer treatments. What makes the company so fascinating? It creates novel “pre-transplant conditioning therapies,” drugs which are designed to attack specific targets in order to "deplete or condition" them prior to, ... |
Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASHActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today highlighted high rates of Complete Remission (CR/CRi) and rates of measurable residual disease (MRD) negativity with improved overall survival in its Actimab-A CLAG-M combination trial in high-risk patients with relapsed or refractory (r/r) acute myeloid leukemia (AML). These data were detailed in an oral presentation at the 64th Annual ASH Meeting & Sympos |
Actinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in AML Patients Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to be CD33 NegativeActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced that it has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. Dr. Siddhartha Mukherjee, MD, DPhil, Assistant Professor of Medicine a |
ATNM Price Returns
| 1-mo | 19.12% |
| 3-mo | 12.02% |
| 6-mo | 123.22% |
| 1-year | 136.63% |
| 3-year | 67.77% |
| 5-year | -35.40% |
| YTD | 14.65% |
| 2022 | 77.20% |
| 2021 | -22.95% |
| 2020 | 19.43% |
| 2019 | -44.18% |
| 2018 | -40.91% |
Loading social stream, please wait...